<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001598</url>
  </required_header>
  <id_info>
    <org_study_id>09-03-0131</org_study_id>
    <nct_id>NCT01001598</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita</brief_title>
  <official_title>Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fanconi anemia (FA) and Dyskeratosis congenita (DC) are inherited bone marrow failure
      syndromes. The current androgen treatments (e.g., oxymetholone) used to treat FA and DC can
      cause unwanted masculinizing side effects, indicating a need for a different medication.
      Danazol is a less potent androgen,and may therefore have fewer masculinizing side effects.
      Danazol is currently approved by the Food and Drug Administration (FDA) for the treatment of
      other diseases, but it has never been studied in patients with FA and DC.

      The main purpose of this study is to see if danazol is a safe treatment for FA and DC.
      Specifically,we would like to determine:

        -  the best dose of danazol;

        -  how fast hemoglobin (a protein that carries oxygen in the blood) levels rise in FA and
           DC patients receiving danazol therapy; and

        -  the genetic pattern (known as expression profile) of certain cells in response to
           danazol, which can predict how well people respond to the medication.

      Subjects who enroll in the study will be treated with danazol for up to 24 weeks (about 6
      months), and will have up to 11 study visits, including followup visits at 38 weeks (9
      months) and 52 weeks (one year).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients with either Fanconi anemia (FA) or Dyskeratosis congenita (DC) will
      initially receive danazol at a dose of 5 mg/kg/d orally, rounded to the nearest 100 mg. For
      the first 8 weeks, the patient will be evaluated at weeks 2, 5, and 8 for hematologic
      response (HR). If the patient shows a hematological response (either a hemoglobin or platelet
      value no longer meeting blood cell count criteria for protocol inclusion in the absence of
      recent transfusions)within the first 12 weeks on the initial dose, the study drug will be
      continued at this dose for the next 6 weeks. If the patient fails to show any hematologic
      response within the first 12 weeks, the dose will be escalated to 10 mg/kg/day for the next 6
      weeks, and an additional monitoring visit will be required at week 14. If at week 18, the
      patient fails to show any hematological response on the increased dose, the dose will be
      increased to 15 mg/kg/day for another 6 weeks (not to exceed 800 mg/day), and an additional
      monitoring visit will be required at week 20. At 24 weeks, if there is no response to this
      dose the patient will be taken off study drug and classified as a treatment failure, and will
      be monitored at weeks 38 and week 52). After week 24, if the patient continues to show a
      response, however, the study drug may be continued at the discretion of their primary care
      physician, with monitoring at weeks 38 and 52.

      Should the patient lose the hematologic response on 5 or 10 mg/kg/day dosing at any point
      within the first 18 weeks of treatment, the dose will be escalated to 10 or 15 mg/kg/day (not
      to exceed 800 mg/day), respectively. The patient will continue to be evaluated at the next
      visit. If after week 24 no hematologic improvement is seen, the patient is then taken off
      study drug and monitored at weeks 38 and 52.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to under enrollment
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Toxicity Associated With Danazol Therapy: Virilization, and/or New or Progressive Evidence of Either Hepatic or Renal Toxicity at a Grade II Level Using National Cancer Institute Common Toxicity Criteria (NCI-CTC).</measure>
    <time_frame>48 weeks (24 weeks treatment and 24 weeks extension phase)</time_frame>
    <description>All toxicities were collected and adjudicated to definitely-related, possibly-related, or unrelated to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Optimal Dose and Number of Participants With Hematologic Response Rate in Fanconi Anemia (FA) and Dyskeratosis Congenita (DC) Patients Receiving Danazol Therapy</measure>
    <time_frame>12, 18 and 24 weeks</time_frame>
    <description>The optimal dose could not be calculated because the number of participants needed to do this were not enrolled. Hematologic response rate (HR) was calculated for each participant at Week 12, 18, and 24. HR was defined by hemoglobin (Hg), platelets or neutrophil response. Please find the evaluation criteria used below:
Hemoglobin response: Hgb≥8 g/dL if baseline Hgb≤7 g/dL, or Hgb rise ≥1 g/dL from baseline if baseline Hgb&gt;7 g/dL. No RBC transfusion during the 8 weeks prior to response evaluation.
Platelet response: Platelet count ≥30,000/ μL if baseline platelet count ≤20,000/ μL, or platelet count rise &gt;10,000/ μL from baseline if baseline platelet count &gt;20,000/ μL. No platelet transfusion during the 4 weeks prior to response evaluation.
ANC response: ANC count ≥1,000/ μL if baseline ANC count ≤500/ μL, or ANC count rise &gt;500/ μL from baseline if baseline ANC count &gt;500/ μL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Gene Expression Profile of Progenitor Cells in Response to Danazol, Both to Predict Responsiveness and to Screen for Small Molecules That Show a Profile Similar to That of Responsive Patients</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The gene expression profiles were planned to be run on bone marrow samples collected from patients at baseline and 24 weeks but bone marrow was never collected at 24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Fanconi Anemia</condition>
  <condition>Dyskeratosis Congenita</condition>
  <arm_group>
    <arm_group_label>danazol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with either Fanconi anemia or Dyskeratosis congenita</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danazol</intervention_name>
    <description>Dosage is done according to weight; capsules are 50, 100, 200 mg</description>
    <arm_group_label>danazol</arm_group_label>
    <other_name>Danocrine, Danol, Danatrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be diagnosed with FA that is documented by a positive test for increased
             chromosomal breakage with mitomycin C or diepoxybutane. DC patients must have clinical
             features consistent with the diagnosis, abnormally short lymphocyte telomeres &lt; 1st
             centile by flow-FISH evaluation, or mutation in one of the known DC genes (DKC1, TERT,
             TERC, TINF2, NOP10, NHP2).

          2. At least the following peripheral blood cytopenias: (without transfusion) Absolute
             neutrophil count &lt; 500/uL or Platelet count &lt; 30,000/uL or Hemoglobin &lt; 8.0 gm/dl

          3. Negative pregnancy test by hCG testing, if of child-bearing potential.

          4. Agreement to use a medically approved form of birth control, if of child-bearing
             potential.

          5. Signed informed consent by the patient or legally authorized representative.

          6. Patients must be either 3 years of age or &gt; 14 kg.

        Exclusion Criteria:

          1. Malignancy

          2. Concurrent enrollment in any other study using an investigational drug.

          3. Concurrent use of anticoagulants.

          4. Use of androgen therapy within last three months.

          5. Patients with liver disease as defined by SGOT, SGPT or bilirubin greater than the
             upper limit of normal.

          6. Patients with renal disease as defined by serum creatinine greater than the upper
             limit of normal for age.

          7. Patients less than either 3 years of age or 14 kg.

          8. Patients who have HLA matched sibling donors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin A Sieff, MB.BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2009</study_first_posted>
  <results_first_submitted>December 20, 2018</results_first_submitted>
  <results_first_submitted_qc>January 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2019</results_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Colin Sieff</investigator_full_name>
    <investigator_title>Director, Bone Marrow Failure Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danazol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from clinic and by letter to Pediatric Hematologists in USA</recruitment_details>
      <pre_assignment_details>Patients with documented Fanconi anemia (FA) or dyskeratosis congenita (DC)
Peripheral blood cytopenias (without transfusion, and at least one result obtained in the past two months that meet criteria): ANC &lt; 500/uL or platelets &lt; 30,000/uL or Hb &lt; 8.0 gm/dl
. Not pregnant
Not on birth control
Consent
3 yrs/ &gt; 14 kg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Danazol</title>
          <description>Subjects with either Fanconi anemia or Dyskeratosis congenita enter a single arm 24 week danazol dose escalation study: Dosage 5mg/kg/d; if no response at 12 weeks increase to 10 mg/kg/d; if no response at 18 weeks increase to 15 mg/kg/d. If no response stop at 24 weeks. Responders continue danazol at discretion of PCP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">3 completed study (2 FA and 1 DC) in 2011</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Hematopoietic Stem Cell Transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Danazol</title>
          <description>Subjects with either Fanconi anemia or Dyskeratosis congenita
danazol: Dosage is done according to weight; capsules are 50, 100, 200 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Toxicity Associated With Danazol Therapy: Virilization, and/or New or Progressive Evidence of Either Hepatic or Renal Toxicity at a Grade II Level Using National Cancer Institute Common Toxicity Criteria (NCI-CTC).</title>
        <description>All toxicities were collected and adjudicated to definitely-related, possibly-related, or unrelated to the treatment.</description>
        <time_frame>48 weeks (24 weeks treatment and 24 weeks extension phase)</time_frame>
        <population>4 patients with Fanconi anemia and 1 with dyskeratosis congenita</population>
        <group_list>
          <group group_id="O1">
            <title>Danazol</title>
            <description>Subjects with either Fanconi anemia or Dyskeratosis congenita enter a single arm 24 week danazol dose escalation study: Dosage 5mg/kg/d; if no response at 12 weeks increase to 10 mg/kg/d; if no response at 18 weeks increase to 15 mg/kg/d. If no response stop at 24 weeks. Responders continue danazol at discretion of PCP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicity Associated With Danazol Therapy: Virilization, and/or New or Progressive Evidence of Either Hepatic or Renal Toxicity at a Grade II Level Using National Cancer Institute Common Toxicity Criteria (NCI-CTC).</title>
          <description>All toxicities were collected and adjudicated to definitely-related, possibly-related, or unrelated to the treatment.</description>
          <population>4 patients with Fanconi anemia and 1 with dyskeratosis congenita</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virilization - definitely related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic - possibly related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Optimal Dose and Number of Participants With Hematologic Response Rate in Fanconi Anemia (FA) and Dyskeratosis Congenita (DC) Patients Receiving Danazol Therapy</title>
        <description>The optimal dose could not be calculated because the number of participants needed to do this were not enrolled. Hematologic response rate (HR) was calculated for each participant at Week 12, 18, and 24. HR was defined by hemoglobin (Hg), platelets or neutrophil response. Please find the evaluation criteria used below:
Hemoglobin response: Hgb≥8 g/dL if baseline Hgb≤7 g/dL, or Hgb rise ≥1 g/dL from baseline if baseline Hgb&gt;7 g/dL. No RBC transfusion during the 8 weeks prior to response evaluation.
Platelet response: Platelet count ≥30,000/ μL if baseline platelet count ≤20,000/ μL, or platelet count rise &gt;10,000/ μL from baseline if baseline platelet count &gt;20,000/ μL. No platelet transfusion during the 4 weeks prior to response evaluation.
ANC response: ANC count ≥1,000/ μL if baseline ANC count ≤500/ μL, or ANC count rise &gt;500/ μL from baseline if baseline ANC count &gt;500/ μL.</description>
        <time_frame>12, 18 and 24 weeks</time_frame>
        <population>2 participants withdrew before HR could be assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Danazol</title>
            <description>Subjects with either Fanconi anemia or Dyskeratosis congenita enter a single arm 24 week danazol dose escalation study: Dosage 5mg/kg/d; if no response at 12 weeks increase to 10 mg/kg/d; if no response at 18 weeks increase to 15 mg/kg/d. If no response stop at 24 weeks. Responders continue danazol at discretion of PCP.</description>
          </group>
        </group_list>
        <measure>
          <title>The Optimal Dose and Number of Participants With Hematologic Response Rate in Fanconi Anemia (FA) and Dyskeratosis Congenita (DC) Patients Receiving Danazol Therapy</title>
          <description>The optimal dose could not be calculated because the number of participants needed to do this were not enrolled. Hematologic response rate (HR) was calculated for each participant at Week 12, 18, and 24. HR was defined by hemoglobin (Hg), platelets or neutrophil response. Please find the evaluation criteria used below:
Hemoglobin response: Hgb≥8 g/dL if baseline Hgb≤7 g/dL, or Hgb rise ≥1 g/dL from baseline if baseline Hgb&gt;7 g/dL. No RBC transfusion during the 8 weeks prior to response evaluation.
Platelet response: Platelet count ≥30,000/ μL if baseline platelet count ≤20,000/ μL, or platelet count rise &gt;10,000/ μL from baseline if baseline platelet count &gt;20,000/ μL. No platelet transfusion during the 4 weeks prior to response evaluation.
ANC response: ANC count ≥1,000/ μL if baseline ANC count ≤500/ μL, or ANC count rise &gt;500/ μL from baseline if baseline ANC count &gt;500/ μL.</description>
          <population>2 participants withdrew before HR could be assessed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR by hemoglobin at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by hemoglobin at 18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by hemoglobin at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by platelets at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by platelets at 18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by platelets at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by neutrophils at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by neutrophils at 18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR by neutrophils at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Gene Expression Profile of Progenitor Cells in Response to Danazol, Both to Predict Responsiveness and to Screen for Small Molecules That Show a Profile Similar to That of Responsive Patients</title>
        <description>The gene expression profiles were planned to be run on bone marrow samples collected from patients at baseline and 24 weeks but bone marrow was never collected at 24 weeks.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Baseline samples were too noisy to determine gene expression.</population>
        <group_list>
          <group group_id="O1">
            <title>Danazol</title>
            <description>Subjects with either Fanconi anemia or Dyskeratosis congenita enter a single arm 24 week danazol dose escalation study: Dosage 5mg/kg/d; if no response at 12 weeks increase to 10 mg/kg/d; if no response at 18 weeks increase to 15 mg/kg/d. If no response stop at 24 weeks. Responders continue danazol at discretion of PCP.</description>
          </group>
        </group_list>
        <measure>
          <title>The Gene Expression Profile of Progenitor Cells in Response to Danazol, Both to Predict Responsiveness and to Screen for Small Molecules That Show a Profile Similar to That of Responsive Patients</title>
          <description>The gene expression profiles were planned to be run on bone marrow samples collected from patients at baseline and 24 weeks but bone marrow was never collected at 24 weeks.</description>
          <population>Baseline samples were too noisy to determine gene expression.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Phase I/II Study</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Danazol started at 5 mg/kg/day (200 mg/day); day 9 a rash that on her hands and spread to the rest of her body diagnosed as hives. Also on birth control (Altavera). Dermatologist at BCH recommended against re-starting the danazol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Virilization</sub_title>
                <description>Clitoral and phallic enlargement</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <description>Enlargement of the left lobe</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood changes</sub_title>
                <description>Probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin A. Sieff</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>617 919-4241</phone>
      <email>colin.sieff@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

